Weiss Asset Management LP Neurocrine Biosciences Inc Transaction History

Weiss Asset Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$130.4 - $143.74 $1.64 Million - $1.81 Million	-12,586 Reduced 86.82%	1,910 $263,000
Q4 2023 Feb 12, 2024	BUY	$106.07 - $132.76 $1.54 Million - $1.92 Million	14,496 New	14,496 $1.91 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $322,105 - $377,335	3,500 New	3,500 $372,000
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $537,336 - $978,091	-7,865 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $255,073 - $338,137	4,358 Added 124.27%	7,865 $610,000
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $168,230 - $214,908	3,507	3,507 $215,000

632

93.9M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Weiss Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Weiss Asset Management LP with notifications on news.